Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform
Bang Zheng, Amelia C A Green, John Tazare, Helen J Curtis, Louis Fisher, Linda Nab, Anna Schultze, Viyaasan Mahalingasivam, Edward P K Parker, William J Hulme, Sebastian C J Bacon, Nicholas J Devito, Christopher Bates, David Evans, Peter Inglesby, Henry Drysdale, Simon Davy, Jonathan Cockburn, Caroline E Morton, George Hickman, Tom Ward, Rebecca M Smith, John Parry, Frank Hester, Sam Harper, Amir Mehrkar, Rosalind M Eggo, Alex J Walker, Stephen J W Evans, Ian J Douglas, Brian Mackenna, Ben Goldacre, Laurie A Tomlinson
BMJ, doi:10.1136/bmj-2022-071932
Objective To compare the effectiveness of sotrovimab (a neutralising monoclonal antibody) with molnupiravir (an antiviral) in preventing severe outcomes of covid-19 in adult patients infected with SARS-CoV-2 in the community and at high risk of severe outcomes from covid-19.
Design Observational cohort study with the OpenSAFELY platform. setting With the approval of NHS England, a real world cohort study was conducted with the OpenSAFELY-TPP platform (a secure, transparent, open source software platform for analysis of NHS electronic health records), and patient level electronic health record data were obtained from 24 million people registered with a general practice in England that uses TPP software. The primary care data were securely linked with data on SARS-CoV-2 infection and treatments, hospital admission, and death, over a period when both drug treatments were frequently prescribed in community settings.
ParticiPants Adult patients with covid-19 in the community at high risk of severe outcomes from covid-19, treated with sotrovimab or molnupiravir from 16 December 2021. interventiOns Sotrovimab or molnupiravir given in the community by covid-19 medicine delivery units.
Main OutcOMe Measures Admission to hospital with covid-19 (ie, with covid-19 as the primary diagnosis) or death from covid-19 (ie, with covid-19 as the underlying or contributing cause of death) within 28 days of the start of treatment.
results Between 16 December 2021 and 10 February 2022, 3331 and 2689 patients were treated with sotrovimab and molnupiravir, respectively, with no substantial differences in baseline characteristics. Mean age of all 6020 patients was 52 (standard deviation 16) years; 59% were women, 89% were white, and 88% had received three or more covid-19 vaccinations. Within 28 days of the start of treatment, 87 (1.4%) patients were admitted to hospital or died of infection from SARS-CoV-2 (32 treated with sotrovimab and 55 with molnupiravir). Cox proportional hazards models stratified by area showed that after adjusting for demographic information, high risk cohort categories, vaccination status, calendar time, body mass index, and other comorbidities, treatment with sotrovimab was associated with a substantially lower risk than treatment with molnupiravir (hazard ratio 0.54, 95% confidence interval 0.33 to 0.88, P=0.01). Consistent results were found from propensity score weighted Cox models (0.50, 0.31 to 0.81, P=0.005) and when restricted to people who were fully vaccinated (0.53, 0.31 to 0.90, P=0.02). No substantial effect modifications by other characteristics were detected (all P values for interaction >0.10). The findings were
References
Austin, An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies, Multivariate Behav Res,
doi:10.1080/00273171.2011.568786Bager, Wohlfahrt, Bhatt, study group. Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study, Lancet Infect Dis,
doi:10.1016/S1473-3099(22)00154-2Bernal, Da Silva, Musungaie, Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients, N Engl J Med,
doi:10.1056/NEJMoa2116044Bruel, Hadjadj, Maes, Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies, Nat Med,
doi:10.1038/s41591-022-01792-5Dal-Ré, Becker, Bottieau, Holm, Availability of oral antivirals against SARS-CoV-2 infection and the requirement for an ethical prescribing approach, Lancet Infect Dis,
doi:10.1016/S1473-3099(22)00119-0Grint, Wing, Gibbs, Accident and emergency (AE) attendance in England following infection with SARS-CoV-2 Omicron or Delta, medRxiv,
doi:10.1101/2022.05.03.22274602Gupta, Gonzalez-Rojas, Juarez, Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab, N Engl J Med,
doi:10.1056/NEJMoa2107934Gupta, Gonzalez-Rojas, Juarez, Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial, JAMA,
doi:10.1001/jama.2022.2832Hoffmann, Krüger, Schulz, The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic, Cell,
doi:10.1016/j.cell.2021.12.032Jo, Kim, Radnaabaatar, Model-based cost-effectiveness analysis of oral antivirals against SARS-CoV-2 in Korea, Epidemiol Health,
doi:10.4178/epih.e2022034Nhs, Neutralising monoclonal antibodies (nMABs) or antivirals for non-hospitalised patients with COVID-19
Tada, Zhou, Dcosta, Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies, EBioMedicine,
doi:10.1016/j.ebiom.2022.103944Takashita, Yamayoshi, Simon, Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants, N Engl J Med,
doi:10.1056/NEJMc2207519Taylor, Adams, Hufford, De La Torre, Winthrop et al., Neutralizing monoclonal antibodies for treatment of COVID-19, Nat Rev Immunol,
doi:10.1038/s41577-021-00542-xVangeel, Chiu, Jonghe, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern, Antiviral Res,
doi:10.1016/j.antiviral.2022.105252{ 'indexed': { 'date-parts': [[2022, 11, 18]],
'date-time': '2022-11-18T06:01:26Z',
'timestamp': 1668751286696},
'reference-count': 30,
'publisher': 'BMJ',
'license': [ { 'start': { 'date-parts': [[2022, 11, 16]],
'date-time': '2022-11-16T00:00:00Z',
'timestamp': 1668556800000},
'content-version': 'unspecified',
'delay-in-days': 0,
'URL': 'http://creativecommons.org/licenses/by/4.0/'}],
'funder': [{'DOI': '10.13039/100010269', 'name': 'Wellcome Trust', 'doi-asserted-by': 'publisher'}],
'content-domain': {'domain': ['bmj.com'], 'crossmark-restriction': True},
'abstract': '<jats:title>Abstract</jats:title>\n'
' <jats:sec>\n'
' <jats:title>Objective</jats:title>\n'
' <jats:p>To compare the effectiveness of sotrovimab (a neutralising monoclonal '
'antibody) with molnupiravir (an antiviral) in preventing severe outcomes of covid-19 in adult '
'patients infected with SARS-CoV-2 in the community and at high risk of severe outcomes from '
'covid-19.</jats:p>\n'
' </jats:sec>\n'
' <jats:sec>\n'
' <jats:title>Design</jats:title>\n'
' <jats:p>Observational cohort study with the OpenSAFELY platform.</jats:p>\n'
' </jats:sec>\n'
' <jats:sec>\n'
' <jats:title>Setting</jats:title>\n'
' <jats:p>With the approval of NHS England, a real world cohort study was conducted '
'with the OpenSAFELY-TPP platform (a secure, transparent, open source software platform for '
'analysis of NHS electronic health records), and patient level electronic health record data '
'were obtained from 24 million people registered with a general practice in England that uses '
'TPP software. The primary care data were securely linked with data on SARS-CoV-2 infection '
'and treatments, hospital admission, and death, over a period when both drug treatments were '
'frequently prescribed in community settings.</jats:p>\n'
' </jats:sec>\n'
' <jats:sec>\n'
' <jats:title>Participants</jats:title>\n'
' <jats:p>Adult patients with covid-19 in the community at high risk of severe '
'outcomes from covid-19, treated with sotrovimab or molnupiravir from 16 December '
'2021.</jats:p>\n'
' </jats:sec>\n'
' <jats:sec>\n'
' <jats:title>Interventions</jats:title>\n'
' <jats:p>Sotrovimab or molnupiravir given in the community by covid-19 medicine '
'delivery units.</jats:p>\n'
' </jats:sec>\n'
' <jats:sec>\n'
' <jats:title>Main outcome measures</jats:title>\n'
' <jats:p>Admission to hospital with covid-19 (ie, with covid-19 as the primary '
'diagnosis) or death from covid-19 (ie, with covid-19 as the underlying or contributing cause '
'of death) within 28 days of the start of treatment.</jats:p>\n'
' </jats:sec>\n'
' <jats:sec>\n'
' <jats:title>Results</jats:title>\n'
' <jats:p>Between 16 December 2021 and 10 February 2022, 3331 and 2689 patients '
'were treated with sotrovimab and molnupiravir, respectively, with no substantial differences '
'in baseline characteristics. Mean age of all 6020 patients was 52 (standard deviation 16) '
'years; 59% were women, 89% were white, and 88% had received three or more covid-19 '
'vaccinations. Within 28 days of the start of treatment, 87 (1.4%) patients were admitted to '
'hospital or died of infection from SARS-CoV-2 (32 treated with sotrovimab and 55 with '
'molnupiravir). Cox proportional hazards models stratified by area showed that after adjusting '
'for demographic information, high risk cohort categories, vaccination status, calendar time, '
'body mass index, and other comorbidities, treatment with sotrovimab was associated with a '
'substantially lower risk than treatment with molnupiravir (hazard ratio 0.54, 95% confidence '
'interval 0.33 to 0.88, P=0.01). Consistent results were found from propensity score weighted '
'Cox models (0.50, 0.31 to 0.81, P=0.005) and when restricted to people who were fully '
'vaccinated (0.53, 0.31 to 0.90, P=0.02). No substantial effect modifications by other '
'characteristics were detected (all P values for interaction >0.10). The findings were '
'similar in an exploratory analysis of patients treated between 16 February and 1 May 2022 '
'when omicron BA.2 was the predominant variant in England.</jats:p>\n'
' </jats:sec>\n'
' <jats:sec>\n'
' <jats:title>Conclusions</jats:title>\n'
' <jats:p>In routine care of adult patients in England with covid-19 in the '
'community, at high risk of severe outcomes from covid-19, those who received sotrovimab were '
'at lower risk of severe outcomes of covid-19 than those treated with molnupiravir.</jats:p>\n'
' </jats:sec>',
'DOI': '10.1136/bmj-2022-071932',
'type': 'journal-article',
'created': { 'date-parts': [[2022, 11, 17]],
'date-time': '2022-11-17T01:12:28Z',
'timestamp': 1668647548000},
'page': 'e071932',
'update-policy': 'http://dx.doi.org/10.1136/crossmarkpolicy',
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': 'Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 '
'outcomes in patients in the community: observational cohort study with the OpenSAFELY platform',
'prefix': '10.1136',
'author': [ {'given': 'Bang', 'family': 'Zheng', 'sequence': 'first', 'affiliation': []},
{'given': 'Amelia C A', 'family': 'Green', 'sequence': 'additional', 'affiliation': []},
{'given': 'John', 'family': 'Tazare', 'sequence': 'additional', 'affiliation': []},
{'given': 'Helen J', 'family': 'Curtis', 'sequence': 'additional', 'affiliation': []},
{'given': 'Louis', 'family': 'Fisher', 'sequence': 'additional', 'affiliation': []},
{'given': 'Linda', 'family': 'Nab', 'sequence': 'additional', 'affiliation': []},
{'given': 'Anna', 'family': 'Schultze', 'sequence': 'additional', 'affiliation': []},
{'given': 'Viyaasan', 'family': 'Mahalingasivam', 'sequence': 'additional', 'affiliation': []},
{'given': 'Edward P K', 'family': 'Parker', 'sequence': 'additional', 'affiliation': []},
{'given': 'William J', 'family': 'Hulme', 'sequence': 'additional', 'affiliation': []},
{'given': 'Sebastian C J', 'family': 'Bacon', 'sequence': 'additional', 'affiliation': []},
{'given': 'Nicholas J', 'family': 'DeVito', 'sequence': 'additional', 'affiliation': []},
{'given': 'Christopher', 'family': 'Bates', 'sequence': 'additional', 'affiliation': []},
{'given': 'David', 'family': 'Evans', 'sequence': 'additional', 'affiliation': []},
{'given': 'Peter', 'family': 'Inglesby', 'sequence': 'additional', 'affiliation': []},
{'given': 'Henry', 'family': 'Drysdale', 'sequence': 'additional', 'affiliation': []},
{'given': 'Simon', 'family': 'Davy', 'sequence': 'additional', 'affiliation': []},
{'given': 'Jonathan', 'family': 'Cockburn', 'sequence': 'additional', 'affiliation': []},
{'given': 'Caroline E', 'family': 'Morton', 'sequence': 'additional', 'affiliation': []},
{'given': 'George', 'family': 'Hickman', 'sequence': 'additional', 'affiliation': []},
{'given': 'Tom', 'family': 'Ward', 'sequence': 'additional', 'affiliation': []},
{'given': 'Rebecca M', 'family': 'Smith', 'sequence': 'additional', 'affiliation': []},
{'given': 'John', 'family': 'Parry', 'sequence': 'additional', 'affiliation': []},
{'given': 'Frank', 'family': 'Hester', 'sequence': 'additional', 'affiliation': []},
{'given': 'Sam', 'family': 'Harper', 'sequence': 'additional', 'affiliation': []},
{'given': 'Amir', 'family': 'Mehrkar', 'sequence': 'additional', 'affiliation': []},
{'given': 'Rosalind M', 'family': 'Eggo', 'sequence': 'additional', 'affiliation': []},
{'given': 'Alex J', 'family': 'Walker', 'sequence': 'additional', 'affiliation': []},
{'given': 'Stephen J W', 'family': 'Evans', 'sequence': 'additional', 'affiliation': []},
{'given': 'Ian J', 'family': 'Douglas', 'sequence': 'additional', 'affiliation': []},
{'given': 'Brian', 'family': 'MacKenna', 'sequence': 'additional', 'affiliation': []},
{'given': 'Ben', 'family': 'Goldacre', 'sequence': 'additional', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0001-8848-9493',
'authenticated-orcid': False,
'given': 'Laurie A',
'family': 'Tomlinson',
'sequence': 'additional',
'affiliation': []}],
'member': '239',
'published-online': {'date-parts': [[2022, 11, 16]]},
'reference': [ { 'key': '2022111621001198000_379.nov16_9.e071932.1',
'doi-asserted-by': 'publisher',
'DOI': '10.1136/bmj.m3379'},
{ 'key': '2022111621001198000_379.nov16_9.e071932.2',
'doi-asserted-by': 'publisher',
'DOI': '10.1101/2022.03.07.22272026'},
{ 'key': '2022111621001198000_379.nov16_9.e071932.3',
'unstructured': 'NHS. Neutralising monoclonal antibodies (nMABs) or antivirals for '
'non-hospitalised patients with COVID-19. 2021. '
'https://www.cas.mhra.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=103186'},
{ 'key': '2022111621001198000_379.nov16_9.e071932.4',
'doi-asserted-by': 'publisher',
'DOI': '10.1056/NEJMoa2107934'},
{ 'key': '2022111621001198000_379.nov16_9.e071932.5',
'doi-asserted-by': 'publisher',
'DOI': '10.1056/NEJMoa2116044'},
{ 'key': '2022111621001198000_379.nov16_9.e071932.6',
'doi-asserted-by': 'publisher',
'DOI': '10.1136/bmj.o443'},
{ 'key': '2022111621001198000_379.nov16_9.e071932.7',
'unstructured': 'NHS. Interim Clinical Commissioning Policy: Antivirals or neutralising '
'monoclonal antibodies for non-hospitalised patients with COVID-19. 2022. '
'https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2021/12/C1650-interim-ccp-antivirals-or-neutralising-monoclonal-antibodies-non-hospitalised-patients-with-covid19-v6.pdf'},
{ 'key': '2022111621001198000_379.nov16_9.e071932.8',
'unstructured': 'UK Health Security Agency. SARS-CoV-2 variants of concern and variants '
'under investigation in England: technical briefing 43. 2022. '
'https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1086494/Technical-Briefing-43-28.06.22.pdf'},
{ 'key': '2022111621001198000_379.nov16_9.e071932.9',
'doi-asserted-by': 'publisher',
'DOI': '10.1080/00273171.2011.568786'},
{ 'key': '2022111621001198000_379.nov16_9.e071932.10',
'doi-asserted-by': 'publisher',
'DOI': '10.1001/jama.2022.2832'},
{ 'key': '2022111621001198000_379.nov16_9.e071932.11',
'doi-asserted-by': 'publisher',
'DOI': '10.1038/s41586-021-04386-2'},
{ 'key': '2022111621001198000_379.nov16_9.e071932.12',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.antiviral.2022.105252'},
{ 'key': '2022111621001198000_379.nov16_9.e071932.13',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.cell.2021.12.032'},
{ 'key': '2022111621001198000_379.nov16_9.e071932.14',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.ebiom.2022.103944'},
{ 'key': '2022111621001198000_379.nov16_9.e071932.15',
'unstructured': 'National Institutes of Health COVID-19 Treatment Guidelines Panel. '
'Therapeutic Management of Nonhospitalized Adults With COVID-19. 2022. '
'https://www.covid19treatmentguidelines.nih.gov/management/clinical-management-of-adults/nonhospitalized-adults-therapeutic-management/'},
{ 'key': '2022111621001198000_379.nov16_9.e071932.16',
'doi-asserted-by': 'publisher',
'DOI': '10.1038/s41591-022-01792-5'},
{ 'key': '2022111621001198000_379.nov16_9.e071932.17',
'doi-asserted-by': 'publisher',
'DOI': '10.1038/s41586-022-04594-4'},
{ 'key': '2022111621001198000_379.nov16_9.e071932.18',
'doi-asserted-by': 'publisher',
'DOI': '10.1056/NEJMc2207519'},
{ 'key': '2022111621001198000_379.nov16_9.e071932.19',
'doi-asserted-by': 'publisher',
'DOI': '10.1038/s41586-022-04856-1'},
{ 'key': '2022111621001198000_379.nov16_9.e071932.20',
'unstructured': 'UK Health Security Agency. SARS-CoV-2 therapeutics technical briefing 3. '
'2022. '
'https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1074186/therapeutics-programme-technical-briefing-3.pdf'},
{ 'key': '2022111621001198000_379.nov16_9.e071932.21',
'doi-asserted-by': 'publisher',
'DOI': '10.1136/dtb.2022.000008'},
{ 'key': '2022111621001198000_379.nov16_9.e071932.22',
'doi-asserted-by': 'publisher',
'DOI': '10.1038/s41577-021-00542-x'},
{ 'key': '2022111621001198000_379.nov16_9.e071932.23',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/S1473-3099(22)00119-0'},
{ 'key': '2022111621001198000_379.nov16_9.e071932.24',
'unstructured': 'European Medicines Agency. Sotrovimab (also known as VIR-7831 and '
'GSK4182136) - COVID19 - Article-5(3) procedure: Conditions of use, '
'conditions for distribution and patients targeted and conditions for '
'safety monitoring. 2021. '
'https://www.ema.europa.eu/en/documents/referral/sotrovimab-also-known-vir-7831-gsk4182136-covid19-article-53-procedure-assessment-report_en.pdf'},
{ 'key': '2022111621001198000_379.nov16_9.e071932.25',
'unstructured': 'European Medicines Agency. Lagevrio (also known as molnupiravir or MK '
'4482) - COVID-19 - Article-5(3) procedure: Assessment report. 2021. '
'https://www.ema.europa.eu/en/documents/referral/lagevrio-also-known-molnupiravir-mk-4482-covid-19-article-53-procedure-assessment-report_en.pdf'},
{ 'key': '2022111621001198000_379.nov16_9.e071932.26',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/S1473-3099(22)00154-2'},
{ 'key': '2022111621001198000_379.nov16_9.e071932.27',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/S0140-6736(22)00462-7'},
{ 'key': '2022111621001198000_379.nov16_9.e071932.28',
'doi-asserted-by': 'publisher',
'DOI': '10.1101/2022.05.03.22274602'},
{ 'key': '2022111621001198000_379.nov16_9.e071932.29',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/S0140-6736(21)02316-3'},
{ 'key': '2022111621001198000_379.nov16_9.e071932.30',
'doi-asserted-by': 'publisher',
'DOI': '10.4178/epih.e2022034'}],
'container-title': 'BMJ',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'http://data.bmj.org/tdm/10.1136/bmj-2022-071932',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://syndication.highwire.org/content/doi/10.1136/bmj-2022-071932',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2022, 11, 17]],
'date-time': '2022-11-17T05:00:56Z',
'timestamp': 1668661256000},
'score': 1,
'resource': {'primary': {'URL': 'https://www.bmj.com/lookup/doi/10.1136/bmj-2022-071932'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2022, 11, 16]]},
'references-count': 30,
'alternative-id': ['10.1136/bmj-2022-071932'],
'URL': 'http://dx.doi.org/10.1136/bmj-2022-071932',
'relation': {},
'ISSN': ['1756-1833'],
'subject': ['General Engineering'],
'container-title-short': 'BMJ',
'published': {'date-parts': [[2022, 11, 16]]}}
